Kris Cameron Wood
Assistant Professor of Pharmacology & Cancer Biology
Appointments and Affiliations
- Assistant Professor of Pharmacology & Cancer Biology
- Assistant Professor of Biomedical Engineering
- Member of the Duke Cancer Institute
- Email Address: firstname.lastname@example.org
- Ph.D. Massachusetts Institute of Technology, 2007
- B.S. University of Kentucky at Lexington, 2002
More effective anticancer therapeutic strategies, many of which are based on functional genomics. Examples of projects include: a miniaturized screening platform, tools to systematically map the signaling pathways controlling anticancer drug responses, high-throughput computational methods to discover anticancer drug combinations, design of therapeutic strategies to reverse or prevent drug resistance, and systematic credentialing of mutations uncovered through cancer genome sequencing projects.
- MOLCAN 780: Graduate Student Seminar
- MOLCAN 818: Molecular Mechanisms of Oncogenesis
- PHARM 393: Research Independent Study
- PHARM 394: Research Independent Study
- PHARM 493: Research Independent Study
- PHARM 494: Research Independent Study
- PHARM 780S: Graduate Student Seminar
- PHARM 818: Molecular Mechanisms of Oncogenesis
In the News
- The Challenges of Combating Cancer Drug Resistance (Nov 19, 2015 | Duke Research Blog )
- Researchers Map Paths to Cancer Drug Resistance (Jan 5, 2015)
- Ali, M; Kaltenbrun, E; Anderson, GR; Stephens, SJ; Arena, S; Bardelli, A; Counter, CM; Wood, KC, Codon bias imposes a targetable limitation on KRAS-driven therapeutic resistance., Nature Communications, vol 8 (2017) [10.1038/ncomms15617] [abs].
- Price, AM; Dai, J; Bazot, Q; Patel, L; Nikitin, PA; Djavadian, R; Winter, PS; Salinas, CA; Barry, AP; Wood, KC; Johannsen, EC; Letai, A; Allday, MJ; Luftig, MA, Epstein-Barr virus ensures B cell survival by uniquely modulating apoptosis at early and late times after infection., eLife, vol 6 (2017) [10.7554/elife.22509] [abs].
- Wood, KC, Suppressing oncogenic transcription with a little healthy competition., Science Translational Medicine, vol 9 no. 374 (2017) [10.1126/scitranslmed.aal5000] [abs].
- Wood, KC, An EXITS strategy for decreasing cancer risk in women., Science Translational Medicine, vol 8 no. 368 (2016) [10.1126/scitranslmed.aal2806] [abs].
- Anderson, GR; Wardell, SE; Cakir, M; Crawford, L; Leeds, JC; Nussbaum, DP; Shankar, PS; Soderquist, RS; Stein, EM; Tingley, JP; Winter, PS; Zieser-Misenheimer, EK; Alley, HM; Yllanes, A; Haney, V; Blackwell, KL; McCall, SJ; McDonnell, DP; Wood, KC, PIK3CA mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translation., Science Translational Medicine, vol 8 no. 369 (2016) [10.1126/scitranslmed.aae0348] [abs].